Conference Report: DIA/PhRMA workshop on DBS sampling in the pharmaceutical industry: methodology, implementation & best practices-Reference-Cited by-同舟云学术

Conference Report: DIA/PhRMA workshop on DBS sampling in the pharmaceutical industry: methodology, implementation & best practices

Published:2010-08 Issue:8 Volume:2 Page:1355-1359
ISSN:1757-6180
Container-title:Bioanalysis
language:en
Short-container-title:Bioanalysis

Author:

Evans Christopher A¹,Bruce Christopher²,Emmons Gary T³,Gallenberg Lori⁴,Ji Qin C⁵,Kinter Lewis B⁶,Musvasva Eunice⁷,Wickremsinhe Enaksha⁸

Affiliation:

1. GlaxoSmithKline, 709 Swedeland Rd, Mailstop UW 2110, King of Prussia, PA 19406, USA.

2. Pfizer Research and Development, Sandwich, UK

3. sanofi-aventis, Bridgewater, NJ, USA

4. Abbott, Chicago IL, USA

5. Bristol-Myers Squibb, Princeton, NJ, USA

6. AstraZeneca Pharmaceuticals, Wilmington, DE, USA

7. Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA

8. Eli Lilly and Company, Indianapolis, IN, USA

Abstract

Representing the first industry-led workshop on this topic, the Drug Information Association (DIA) and Pharmaceutical Research and Manufacturers of America (PhRMA) cosponsored a workshop on dried blood spots (DBS) sampling in the pharmaceutical industry. Sampling from DBS on specialty papers is a novel methodology in the area of pharmacokinetics and toxicokinetics that serves to replace conventional plasma analysis for pharmaceutical development. As the awareness around this technology has increased exponentially in recent years, this 1-day symposium aimed to share current best practices for DBS use and implementation, sample collection, handling and associated bioanalysis. The event drew over 150 industry and agency participants; an impressive attendance for a relatively new technology within the industry. Overall, the day was divided into six separate technical sessions plus poster sessions, and included concurrent breakout sessions dedicated to three key areas surrounding DBS implementation: bioanalytical, toxicology/safety assessment and clinical/pharmacokinetics.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Link

http://www.future-science.com/doi/pdf/10.4155/bio.10.101

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Land O’Lakes Workshop on Microsampling: Enabling Broader Adoption;The AAPS Journal;2020-10-23

2. Implementing Dried Blood Spot Sampling for Clinical Pharmacokinetic Determinations: Considerations from the IQ Consortium Microsampling Working Group;The AAPS Journal;2014-12-09

3. Preclinical bridging studies: understanding dried blood spot and plasma exposure profiles;Bioanalysis;2013-01

4. What is next for dried blood spots?;Bioanalysis;2012-08

5. Will ‘green’ aspects of dried blood spot sampling accelerate its implementation and acceptance in the pharmaceutical industry?;Bioanalysis;2012-06